StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho
May 3, 2021 1:43 PM
Mizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat
May 5, 2021 4:39 PM
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update
May 3, 2021 11:58 AM
Form 8-K Sarepta Therapeutics, For: May 03
May 3, 2021 8:53 AM
Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021 8:50 AM
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021 8:50 AM
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
May 3, 2021 8:02 AM
